- Research shows psilocybin produces immediate, substantial and sustained improvements in anxiety and depression
- Global medicinal mushroom market projected to increase by almost $14 billion annually for the next several years
- Pure Extracts is a plant-based extraction company with new vertical in the mushroom space
Recent groundbreaking research indicates that psilocybin-assisted psychotherapy may be effective in treating depression, a debilitating disorder that plagues an estimated 300 million people in the United State. Psilocybin is the main psychoactive ingredient in “magic” mushrooms. With growing interest in the mushroom sector — both psychedelic and functional — companies such as Pure Extract Technologies could see exciting growth and expansion in the future.
A recent National Centre for Mental Health (“NCMH”) article reported that “a small number of studies have been conducted trialing psilocybin on patients with treatment-resistant depression. A person may be defined as having treatment-resistant depression if their symptoms of major-depressive disorder do not subside with attempted treatment from two different classes of antidepressants.”
Results of the tests showed that, after only one week — as well as after three months — depression scores significantly decreased, with the majority of participants experiencing reduced depression severity after three months. That initial test sparked intense interest, and “further research has been conducted with similar findings of efficacy,” the article noted.
“In [a] Johns Hopkins psilocybin research project, they found that 80% of healthy volunteers that returned a month after having one or two doses of psilocybin reported that the experience of taking the drug was in their top five meaningful experiences they’d ever had,” the article continued. “Around 90% reported increased positive mood and greater life satisfaction.” The report goes on to note that additional psilocybin studies have shown that for those with anxiety and patients with life-threatening cancer, the drug produced immediate, substantial and sustained improvements in anxiety and depression.
Pure Extract Technologies recognizes that psychedelic and functional mushroom industries are among the fastest-growing in North America, with the global medicinal mushroom market projected to increase by almost $14 billion annually for the next several years. As the industry transitions to meet these burgeoning needs, few companies appear to be prepared for the new opportunity.
Pure Extracts, however, is a private, plant-based extraction company with a new vertical in the mushroom space. The savvy company is ideally positioned to become a dominant extraction company in the space and a leader in the rapid development and commercialization of functional and medicinal products.
Pure Extracts is focusing on a strategic business model consisting of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to distribute under their own brands; and white labelling, or supplying products in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.
Pure Extracts is positioned to enter the commercial cannabis sector, as well as a new vertical in functional mushrooms, as an experienced producer. Led by a team of qualified experts and providing cutting-edge CO2 extraction technology, the company is set up for long-term strategic distribution and product innovation.
For more information, visit the company’s website at www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://cnw.fm/Pure
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.